Extended Data Table 1.
Demographic and clinical characteristics of patients in the Study and Validation cohorts.
| Variable | Response | Progression | p-value* |
|---|---|---|---|
| UCLA Patients (N=46) | N=22€ | N=24 | |
| Male (%) | 17 (74%) | 19 (79%) | >0.99 |
| Median Age (range) | 65 (45–90) | 64 (36–86) | 0.86£ |
| Median WBC Count (range) | 6.9 (3.9–21.3) | 7.1 (4.0–24.8) | 0.52 |
| Median Pre-TX Tumor Burden in cm (range)¥ | 8.7 (1.1–32.2) | 7.9 (1.1–19.4) | 0.9£ |
| Metastatic Status | |||
| M0 | 3 (13%) | 2 (8%) | 0.13£ |
| M1a | 4 (17%) | 2 (8%) | |
| M1b | 7 (30%) | 6 (25%) | |
| M1c | 8 (35%) | 14 (58%) | |
| Dosing Regimen | |||
| 10Q2W | 9 (39%) | 5 (21%) | 0.2 |
| 10Q3W | 8 (35%) | 8 (33%) | |
| 2Q3W | 5 (22%) | 11 (46%) | |
| BRAF Mutation | |||
| Mutant (# not wild type) | 7 (30%) | 9 (38%) | 0.76 |
| Previous Treatment | |||
| chemotherapy | 3 (13%) | 5 (21%) | 0.7 |
| BRAF or MEK inhibitor | 3 (13%) | 5(21%) | 0.7 |
| immunotherapy | |||
| ipilimumab | 8 (35%) | 13 (54%) | 0.25 |
| other | 7 (30%) | 9 (38%) | 0.76 |
| Pre TX Biopsy Location₠ | |||
| Subcutaneous | 14 (61%) | 11 (46%) | 0.02£ |
| Liver | 0 | 8 (33%) | |
| Lung | 5 (22%) | 1 (4%) | |
| Other | 3 (13%) | 3 (13%) | |
| IGR Patients (N=15) | N=10 | N=5 | |
| Median Age (range) | 55 (26–73) | 60 (38–61) | 0.77£ |
| Male (%) | 4 (40%) | 2 (40%) | >0.99 |
| Metastatic Status | |||
| M0 | 2 (20%) | 0 (0%) | 0.51£ |
| M1a | 3 (30%) | 1 (20%) | |
| M1b | 0 (0%) | 1 (20%) | |
| M1c | 5 (50%) | 3 (60%) | |
| Dosing Regimen | |||
| 10Q2W | 5 (50%) | 2 (40%) | 0.62 |
| 10Q3W | 3 (30%) | 3 (60%) | |
| 2Q3W | 2 (20%) | 0 (0%) | |
| BRAF Mutation | |||
| Mutant (# not wild type) | 4 (40%) | 2 (40%) | >0.99 |
| Previous Treatment | |||
| chemotherapy | 2 (20%) | 3 (60%) | 0.25 |
| BRAF or MEK inhibitor | 2 (20%) | 0 (0%) | 0.52 |
| immunotherapy | |||
| ipilimumab | 4 (40%) | 2 (40%) | >0.99 |
| other | 1 (10%) | 1 (20%) | >0.99 |